Hey, it's your host, Kate Limebaugh and Ryan Knudsen.

Earlier this month, we brought you a two-part story on the biotech startup, Ubiome.

And today, we're bringing those parts together.

Now, you can hear the entire saga in one place.

Ubiome was a biotech company that seemed to have it all.

Public leaders, a promising idea, and lots of venture capital funding.

But eventually, the company had a spectacular downfall.

For the past few years, our colleague Amy Doxer-Marcus and a team of Wall Street Journal reporters

have been covering the rise and fall of Ubiome.

And so, for our story today, Amy's going to take over.

Here she is.

As a reporter, I spend a lot of my time thinking about why healthcare doesn't work for so

many people.

Why cares still seem out of reach for so many?

How medicine seems to focus more on treating disease rather than preventing it?

So back in 2014, I had taken an interest in this company called Ubiome.

At the time, it was a small startup.

But its founders, Jessica Richmond and Zach Apty had big ambitions.

Their product was an at-home test kit, kind of like 23 in me.

But this kit would test the makeup of your microbiome.

The trillions of microbes that live in and on all of us.

The bigger idea behind the company was all about something called citizen science, getting

...